Penumbra PEN
NYSE PEN
$324.82 -2.02 (-0.62%)
At close: Aug 20, 2026 · 1:27 PM UTC

Penumbra (PEN) Net Income towards Common Stockholders (2014 - 2026)

Penumbra (PEN) posted quarterly Net Income towards Common Stockholders of $34.8 million for Q2 2026, down 23.16% year-over-year from $45.3 million in Q2 2025, and up 6.76% quarter-over-quarter from $32.6 million in Q1 2026.

Penumbra (PEN) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends

Penumbra (PEN) has reported Net Income towards Common Stockholders for 13 consecutive years, with $34.8 million the latest figure, recorded in Q2 2026.

  • In Q2 2026, Net Income towards Common Stockholders fell 23.16% year-over-year to $34.8 million; the TTM figure through Jun 2026 stood at $160.5 million (up 8.73% YoY), while the FY2025 annual figure was $177.7 million, up 1168.11% from the prior year.
  • Net Income towards Common Stockholders improved to $34.8 million in Q2 2026 per PEN's latest filing, from $32.6 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $54.2 million in Q4 2023 and bottomed at -$60.2 million in Q2 2024.
  • Historically, Net Income towards Common Stockholders has averaged $19.3 million across 5 years, with a median of $24.2 million in 2023.
  • Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders jumped 10725.32% — and 2024, when it sank 417.78%.
  • Penumbra's Net Income towards Common Stockholders stood at $3.9 million in 2022, then soared by 1298.45% to $54.2 million in 2023, then plunged by 37.88% to $33.7 million in 2024, then jumped by 40.56% to $47.3 million in 2025, then dropped by 26.52% to $34.8 million in 2026.
  • Business Quant data shows PEN's Net Income towards Common Stockholders at $34.8 million in Q2 2026, $32.6 million in Q1 2026, and $47.3 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Abbott Laboratories 198.81 Bn 193.21 Bn 7.27 Bn 928.00 Mn
2 Stryker 127.76 Bn 124.28 Bn 4.50 Bn 1.28 Bn
3 Medtronic 118.77 Bn 109.55 Bn 6.41 Bn 1.26 Bn
4 Boston Scientific 73.25 Bn 72.71 Bn 3.85 Bn 907.00 Mn
5 Edwards Lifesciences 51.93 Bn 47.68 Bn 1.35 Bn 241.40 Mn
6 Dexcom 34.43 Bn 32.49 Bn 830.00 Mn 249.10 Mn
7 GE HealthCare Technologies 33.88 Bn 31.77 Bn 2.18 Bn 574.00 Mn
8 Koninklijke Philips 26.35 Bn 23.03 Bn 4.55 Bn 621.86 Mn
9 Steris 23.11 Bn 22.63 Bn 684.20 Mn 201.00 Mn
10 Penumbra 12.78 Bn 12.12 Bn 264.94 Mn 34.79 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 34.79 Mn
Mar 31, 2026 32.59 Mn
Dec 31, 2025 47.34 Mn
Sep 30, 2025 45.85 Mn
Jun 30, 2025 45.31 Mn
Mar 31, 2025 39.22 Mn
Dec 31, 2024 33.68 Mn
Sep 30, 2024 29.48 Mn
Jun 30, 2024 -60.20 Mn
Mar 31, 2024 11.00 Mn
Dec 31, 2023 54.22 Mn
Sep 30, 2023 9.21 Mn
Jun 30, 2023 18.94 Mn
Mar 31, 2023 8.56 Mn
Dec 31, 2022 3.88 Mn
Sep 30, 2022 -2.27 Mn
Jun 30, 2022 -3.69 Mn
Mar 31, 2022 79,000.00
Dec 31, 2021 -24.63 Mn
Sep 30, 2021 8.03 Mn